WO1997024453A1 - Polypeptides chimeres de surface virale, specifiques d'un recepteur, pour l'incorporation et l'interiorisation d'une particule et d'un virus dans des cellules cibles - Google Patents

Polypeptides chimeres de surface virale, specifiques d'un recepteur, pour l'incorporation et l'interiorisation d'une particule et d'un virus dans des cellules cibles Download PDF

Info

Publication number
WO1997024453A1
WO1997024453A1 PCT/US1996/019196 US9619196W WO9724453A1 WO 1997024453 A1 WO1997024453 A1 WO 1997024453A1 US 9619196 W US9619196 W US 9619196W WO 9724453 A1 WO9724453 A1 WO 9724453A1
Authority
WO
WIPO (PCT)
Prior art keywords
vims
ligand
particle
chimeric
polypeptide
Prior art date
Application number
PCT/US1996/019196
Other languages
English (en)
Inventor
Steven Rosenberg
Original Assignee
Chiron Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corporation filed Critical Chiron Corporation
Priority to CA002240578A priority Critical patent/CA2240578A1/fr
Priority to JP52432697A priority patent/JP2001519647A/ja
Priority to EP96946385A priority patent/EP0880596A1/fr
Publication of WO1997024453A1 publication Critical patent/WO1997024453A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins
    • C07K14/8132—Plasminogen activator inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the invention relates to methods of delivery of genes, proteins, ribozymes, antisense oligonucleotides, small molecules, and other therapeutic agents to target cells. Specifically, the invention relates to methods of internalization in target cells of viruses or particles containing molecular contents that include coding sequences for expression in a cell, and proteins, ribozymes, anti-sense oligonucleotides, small molecules, and other therapeutic agents for initiating, attentuating or inhibiting various molecular and cellular responses.
  • the invention also relates to chimeric viral surface polypeptides for incorporation into viruses or particles, and to particles altered by the addition of a ligand portion of a receptor-specific ligand for internalizing the altered particle and its molecular contents in a target cell.
  • Claimed herein are chimeric viral surface polypeptides , the polynucleotide sequences encoding the chimeras, a virus or particle incorporated with the chimeras, the virus or particles internalized by a target cell, altered particles possessing an intemalizable ligand portion on their surface, and methods of treating diseases using the method ofthe invention for targeting viruses or particles to target cells in a cell specific manner.
  • Tissue specific viral delivery has also been achieved with some success using retroviral vectors and a chimeric protein containing the polypeptide hormone erythropoietin and part ofthe env protein of ectotropic Moloney murine leukemia virus engineered into the virus, as described in Kasahara et al Science 266: 1373-1376 (1994) and PCT application 93/25234 to Y.W. Kan.
  • Non-viral delivery has been accomplished by the injection of naked DNA plasmid containing the coding sequence for the heterologous protein as described in Zhu et al Science 261 : 209-211 (1993).
  • Non-viral delivery has also been accomplished by inserting a coding sequence into conventional vectors that contain conventional control sequences for high level expression, and then incubating the construct with synthetic gene transfer molecules such as polymeric DNA-binding cations like polylysine, protamine, and albumin, linked to cell targeting ligands such as asialoorosomucoid, as described in Wu and Wu, /. Biol. Chem. (1987) 262: 4429-4432; insulin, as described in Hucked et al., Biochem. Pharmacol.
  • liposomes to encapsulate DNA comprising the gene under the control of a variety of tissue-specific or ubiquitously- active promoters, as described in Nabel et al, Proc. Natl. Acad. Sci. USA 90: 11307- 11311 (1993), and Philip et al, Mol. Cell Biol. 14: 2411-2418 (1994).
  • Liposomes are also appropriate for the delivery of other therapeutic agents including proteins and non- protein therapeutic agents.
  • Further non-viral delivery suitable for use includes mechanical delivery systems such as the biolistic approach, as described in Woffendin et al, Proc. Natl. Acad. Sci. USA (1994) 91(24): 11581-11585.
  • the coding sequence and the product of expression of such and other therapeutic agents can be delivered through deposition of photopolymerized hydrogel materials.
  • Other conventional methods for gene delivery that can be used for delivery of the coding sequence include, for example, use of hand held gene transfer particle gun, as described in U.S. 5,149,655; use of ionizing radiation for activating transferred genes, as described in U.S. 5,206,152 and PCT application WO 92/11033.
  • the limitations presently existing in the art of both viral and non-viral delivery include limited success accomplishing sustained, high level tissue specific incorporation of viral or other particles.
  • a chimeric polynucleotide encoding a chimera of a ligand and a viral surface protein for use in delivery of a virus or a particle containing molecular contents for intemalization into target cells
  • the chimera includes a polynucleotide sequence encoding all or a portion of a ligand of a receptor from the LDL-receptor family, and a polynucleotide sequence encoding all or a portion of a viral surface protein, so that the expression product ofthe chimeric polynucleotide forms a chimeric viral surface polypeptide capable of forming an incorporation aggregrate for incorporation of a virus or particle, and capable of forming a binding pair with the receptor for intemalization ofthe virus or particle incorporated by the chimeric viral surface polypeptide into a target cell expressing the receptor, and wherein the virus or particle comprises molecular contents for delivery to a target
  • It is a further object ofthe invention to provide a chimeric polypeptide for incorporation of a vims or particle for targeting a cell for intemalization of the vims or particle for delivery of viral or particle contents that includes a polypeptide sequence including all or a portion of a ligand of a receptor from the LDL-receptor family, and that also includes an additional polypeptide sequence including all or a portion of a viral surface protein, so that the chimeric polypeptide can make up an incorporation aggregrate of these chimeric polypeptides for incorporation of a vims or particle to form an inco ⁇ orated vims or incorporated particle for targeting a cell expressing the receptor.
  • the targeting of a cell expressing the receptor occurs when the ligand forms a binding pair with the receptor for intemalization ofthe incorporated vims or incorporated particle.
  • the vims or particle can contain molecular contents for delivery to the target cell, including but not limited to genes for expression in the target cell, and therapeutics of all kinds for delivery to the target cells.
  • It is another object ofthe invention to provide a method of targeting and internalizing a vims or particle comprising the steps of (a) constructing a chimeric polynucleotide encoding a chimeric polypeptide that includes a polypeptide sequence including all or a portion of a ligand of a receptor from the LDL-receptor family, and that also includes an additional polypeptide sequence including all or a portion of a viral surface protein, (b) expressing the chimeric polynucleotide to form a chimeric viral surface polypeptide (c) incorporating the chimeric viral surface polypeptide into the surface of a vims or particle containing molecular contents to form an incorporated vims or particle, (d) bringing the inco ⁇ orated vims or particle in contact with a target cell expressing the receptor (e) internalizing the vims or particle into the target cell by binding ofthe ligand with the receptor.
  • a further object ofthe invention is to provide for ligand portions ofthe chimeric viral surface polypeptides ofthe invention that include SERPINs (serine protease inhibitors), particularly PAI-1, and also including TFPI.
  • the present invention conceives a method of delivery of genes or other therapeutics using the intemalization mechanism of viral surface proteins, cell surface receptors, and the ligands for these receptors.
  • a ligand is expressed on a vims or other gene delivery particle and this ligand binds to and is internalized by a cell expressing the receptor.
  • the specificity of this event is dependent on the amount and distribution of the receptor on the various cell types, including the target cell.
  • the receptor already has the ligand bound to it, for example erythropoetin bound to the EPO receptor, then a gene delivery particle can not bind to that cell, as described in PCT application 93/25234.
  • the present invention conceives of a chimeric viral surface protein that includes a ligand or a portion of a ligand specific for a receptor of the LDL-receptor family. Use of these ligands surmounts the obstacle of reduced specificity where the receptors are bound to ligands and thereby unable to bind other ligands.
  • the gene delivery particle is decorated with a ligand, which recognizes another ligand: receptor complex.
  • a gene delivery particle expressing PAI-1 ligand will recognize and to bind covalently to active two chain uPA bound to the uPAR receptor.
  • the invention includes all ligands of the LDL-receptor family, and thus can achieve specificities of target cell intemalization on the basis of the cell types that express the receptors of the LDL-receptor family, and also on the basis of cell types that express other receptors that bind other ligands that bind the ligands of the LDL-receptor family, and later, as a ligand complex of one or more polypeptides, and still connected to the original particle to be delivered to a cell, binds the receptor of the LDL-receptor family and is internalized.
  • a "polynucleotide” or a "coding sequence,” as used herein, refers to either RNA or DNA that encodes a specific amino acid sequence or its complementary strand.
  • a polynucleotide may also not encode a polypeptide, such as, for example, an antisene oligonucleotide, or a ribozyme.
  • the DNA or RNA may be single stranded or double stranded.
  • the term a "chimeric polynucleotide” as used herein refers to a polynucleotide sequence that includes part ofthe coding sequences of more than one protein where the proteins are not naturally encoded in close proximity to one another on the same nucleic acid molecule.
  • the coding sequences of two or more proteins are isolated and linked by techniques commonly practiced in the art of recombinant DNA technology.
  • the chimeric polynucleotide molecule will contain one or more regulatory sequences for expression ofthe chimera in appropriate host cells, or in vivo.
  • the regulatory sequences can be naturally associated with one ofthe coding sequences or may be heterologous to one or more ofthe coding sequences.
  • Each coding sequence may have its own regulatory sequences.
  • the chimeric polynucleotide expression product is a chimera of portions of two not-naturally associated polypeptides.
  • chimera of a ligand and a viral surface protein refers to the expression product of a chimeric polynucleotide that encodes a portion of a ligand and a portion of a viral surface protein.
  • the chimera is constructed so that the ligand portion can bind the receptor that the ligand binds in the natural environment, so that the chimeric viral surface protein can inco ⁇ orate into a viral surface to form a chimeric viral envelope, and so that the chimeric viral surface can surround a viral genome much as in the natural environment.
  • the chimera is a dual functioning polypeptide or a multi-functioning polypeptide, retaining at least the function ofthe ligand and the function ofthe viral surface protein that comprise it.
  • inco ⁇ oration aggregrate refers to the phenomenon where a vims or particle is surrounded or encapsulated by a surface protein to form a vesicle surrounded or inco ⁇ orated by the surface protein.
  • inco ⁇ oration aggregrate describes a pool of surface proteins or chimeric surface polypeptides that function to inco ⁇ orate a vims or particle into a vesicle.
  • the vesicle is then defined in part by the qualities ofthe surface protein into which it is inco ⁇ orated.
  • the vesicle can be a vims or a particle, and can be internalized in a target cell based on the specificity ofthe surface protein by which it is inco ⁇ orated.
  • regulatory sequence refers to a nucleic acid sequence encoding one or more elements that are capable of affecting or effecting expression of a gene sequence, including transcription or translation thereof, when the gene sequence is placed in such a position as to subject it to the control thereof.
  • a regulatory sequence can be, for example, a minimal promoter sequence, a complete promoter sequence, an enhancer sequence, an upstream activation sequence ("UAS"), an operator sequence, a downstream termination sequence, a polyadenylation sequence, an optimal 5' leader sequence to optimize initiation of translation, and a Shine-Dalgano sequence.
  • the regulatory sequence can contain a combination enhancer/promoter element.
  • the regulatory sequence that is appropriate for expression of the gene of interest differs depending upon the host system in which the construct is to be expressed. Selection ofthe appropriate regulatory sequences for use herein is within the capability of one skilled in the art. In eukaryotes, for example, such a sequence can include one or more of a promoter sequence and/or a transcription termination sequence. Regulatory sequences suitable for use herein may be derived from any source including a prokaryotic source, an eukaryotic source, a vims, a viral vector, a bacteriophage or a linear or circular plasmid.
  • the regulatory sequence herein can also be a synthetic sequence, for example, one made by combining the UAS of one gene with the remainder of a requisite promoter from another gene, such as the GAPDH/ADH2 hybrid promoter, as described in U.S. Patents number 4,876,197 and 4,880,734.
  • the regulatory sequences suitable for use herein can be any regulatory sequence that is compatible for use with the promoters for expression in a desired host cell. For example, for expression in yeast, a regulatory sequence derived from yeast systems would be desirable.
  • the regulatory sequence can be a sequence naturally associated with the promoters selected for use herein, or can be a synthetic sequence, or partly synthetic or partly derived.
  • the promoters suitable for use herein can be any promoter, including those that are constitutively active or those that are inducible or regulatable.
  • the promoters can be naturally derived or synthetically made. They can be derived from any genes, viral, prokaryotic or eukaryotic.
  • the eukaryotic genes can be yeast or other fungal, insect, mammalian or avian genes. Examples of suitable promoters are described below in the portion relating to expression systems.
  • protein or “polypeptide” or “peptide” used herein in the context of an element ofthe invention include the product of a gene expressed or regulated.
  • the protein, polypeptide, or peptide ofthe invention may be the ligand or the portion ofthe ligand that makes up a chimeric polypeptide for surrounding a vims and binding to a cell surface receptor on cells targeted for viral infection and viral replication of heterologous genes.
  • the protein, polypeptide, or peptide may be a portion ofthe viral surface that makes up the chimeric polypeptide for surrounding a vims and binding to a cell surface receptor on cells targeted for viral infection.
  • the protein, polypeptide or peptide of the invention may also be the non-viral polypeptide expressed by the non-viral coding sequence present in the viral genome for expression in virally infected cells.
  • the terms "protein”, “polypeptide” or “peptide” as used herein also includes “mature protein” and “analogs” thereof and “portions” thereof that are truncations, variants, allelles and derivatives of the mature protein.
  • a portion of as used herein in the context of "a portion of a ligand” and "a portion of a viral surface protein” refers to a portion ofthe entire coding sequence or expression product of a biologically active ligand or viral surface protein, the portion also retaining the biological activity ofthe ligand or the viral surface protein.
  • Biological activity is, for example, in the case ofthe ligand, ligand binding; and in the case ofthe viral surface protein is, for example, the ability to surround, envelop, or encapsulate a vims or particle.
  • Biological activity of a viral surface protein is also indicated by the ability ofthe viral surface protein to become anchored in the membrane that encapsulates the vims or particle.
  • polypeptides As with the term protein or polypeptide, the term "a portion of as used herein also refers to portions of mature proteins and analogs thereof. The analogs may be truncations, variants, alleles, and derivatives ofthe mature protein. Unless specifically mentioned otherwise, the "analogs" possess one or more ofthe bioactivities of the "mature protein.” Thus, polypeptides that are identical or contain at least 60%, preferably 70%, more preferably 80%, and most preferably 90% amino acid sequence homology to the amino acid sequence ofthe mature protein wherever derived, from human or nonhuman sources, are included within this definition.
  • derived from indicates, in the case ofthe portion of a viral surface protein that is "derived from a viral surface of a vims, that the viral surface protein portion used to construct the chimeric viral surface protein of the invention has high sequence homology to the viral surface protein of a native vims.
  • variants refers to "variants of a protein” or “variants of a polypeptide” or “variants of a portion of a protein or a polypeptide”.
  • variants refers to proteins or polypeptides or portions of proteins or polypeptides that contain amino acid substitutions, deletions, or insertions.
  • the amino acid substitutions can be conservative amino acid substitutions or substitutions to eliminate non-essential amino acid residues such as to alter a glycosylation site, a phosphorylation site, an acetylation site, or to minimize misfolding by substitution or deletion of one or more cysteine residues that are not necessary for function.
  • Conservative amino acid substitutions are those that preserve the general charge, hydrophobicity/hydrophilicity and/or steric bulk ofthe amino acid substituted, for example, substitutions between the members ofthe following groups are conservative substitutions: Gly /Ala, Val/Ile/Leu, Asp/Glu, Lys/ Arg, Asn/Gln, and Phe/T ⁇ /Tyr.
  • the analogs herein further include peptides having one or more peptide mimics, also known as peptoids, that possess the bioactivity of the protein.
  • polypeptides containing one or more analog amino acid including, for example, unnatural amino acids, etc.
  • polypeptides with substituted linkages as well as other modifications known in the art, both naturally occurring and non-naturally occurring.
  • polypeptide also does not exclude post- expression modifications ofthe polypeptide, for example, glycosylations, acetylations, phosphorylations and the like.
  • ligand refers to a molecule or complex of molecules that bind a receptor, such as a cell surface protein receptor.
  • a ligand can be a peptide, polypeptide, protein, any other molecule capable of forming a binding pair with a receptor, or any complex of more than one molecule capable of the same.
  • the ligand can also be a portion of a ligand such that the binding portion of the ligand is retained and the portion of the ligand can still bind the receptor.
  • the ligand can also be a portion of a complex that binds the receptor, the portion retaining the ability to bind the receptor and the ability to remain bound to the polypeptide or polypeptides of the complex.
  • the ligand is a ligand complex it can comprise a polypeptide complexed to at least one other polypeptide and forming a binding site for a receptor.
  • the binding between the ligand or the ligand complex and receptor is characterized as high affinity in order that a binding pair is formed; the binding pair may form a non-covalent or covalent bond.
  • Examples of a ligand complex binding a receptor exist with the SERPIN PAI-1 bound to uPA or tPA.
  • uPA is bound to uPAR on the cell surface.
  • uPA will bind PAI-1 covalently and forms a complex separate from uPAR.
  • the complex uPA:PAI-l binds LRP, also on the cell surface.
  • LRP may bind at PAI-1 of the complex or at both PAI-1 and uPA.
  • the binding preceeds intemalization of the complex into the cell by an LRP mediated mechanism.
  • the ligand is part of a ligand complex, the ligand portion retains at least the ability to bind and the polypeptide or polypeptides of the ligand complex, and also at least the ability to bind the receptor of the LDL-receptor family for which it is specific.
  • receptor refers to a protein molecule that binds a ligand to form a binding pair. Receptors are expressed on the cell surface. Binding of a ligand to a receptor often initiates a cellular response, such as for example, intemalization of the ligand: receptor binding pair, or aggregation of receptors on the cell surface. Examples of cell-surface receptors include receptors of the LDL-receptor family, receptors that bind SERPIN :protease complexes, receptors that bind and internalize PAI- 1 and complexes bound to PAI-1, the LRP receptor, the gp330 receptor, and receptors that bind and internalize TFPI.
  • LDL-receptor family refers to the family of low density lipoprotein receptors.
  • the family includes, but is not limited to, the low density lipoprotein receptor (LDLR), the very low density lipoprotein receptor- 1 and very low density lipoprotein receptor -2 (VLDLR-1 and VLDLR-2), the low density lipoprotein- receptor related protein (LRP), glycoprotein 330, and a gp-330-like protein identified in Caenorhabditis elegans (C. elegans) as disclosed in Yochem and Greenwald, Proc. Natl. Acad. Sci. USA 90:4572-4576, (1993). These receptors and their function are disclosed generally in a review article, and the references cited therein, by Strickland et al, FASEB J. 9:890-898, (1995).
  • SERPIN refers to a class of proteins that are serine protease inhibitors.
  • the classification includes such proteins as, for example, PAI-1, ⁇ -1- antitrypsin and ⁇ -1-antichymotrypsin.
  • PAI-1 refers to plasminogen activator inhibitor - 1. Isolation and cloning of PAI-1 is described in Pannekoek et al, EMBO, 5:2539-2544 (1986).
  • tPA tissue type plasminogen activator, a protease capable of activating tissue type plasminogen.
  • uPA refers to urokinase plasminogen activator, a protease capable of activating urokinase plasminogen.
  • uPAR refers to the urokinase plasminogen activator receptor. uPAR is a cell surface receptor that binds urokinase plasminogen activator (uPA).
  • TFPI tissue factor pathway inhibitor
  • PSA prostate specific antigen
  • a binding pair refers to a pair of molecules, usually referring to a protein/protein pair, but does not exclude a protein DNA pair, or a protein/RNA pair in which the components ofthe pair bind specifically to each other with a higher affinity than to a random molecule, such that upon binding, for example, in case of a ligand/receptor interaction, the binding pair triggers a cellular or an intracellular response.
  • the ligand can be one polypeptide molecule, or can be a polypeptide molecule complexed to one or more polypeptide molecules to form a ligand complex.
  • the ligand complex can bind a receptor and form a binding pair.
  • a key aspect ofthe invention is that the ligand for the receptors ofthe invention are specific for ligand complexes of more than one polypeptide, in addition to being specific for single polypeptide ligand. It is believed that the specificity of intemalization which is an object ofthe invention is created in part by ligands that comprises more than one polypeptide complexed together capable of binding a receptor ofthe LDL-receptor family.
  • the binding pair is formally the ligand or the ligand complex, and the binding pair is formed by the complex and the receptor when binding occurs.
  • the binding sites ofthe binding pair may be on any part ofthe ligand, or the ligand complex.
  • the receptor may bind part of both polypeptides of a two polypeptide ligand complex, or may only bind one ofthe polypeptides ofthe complex.
  • the binding pair may be formed by the formation of a covalent bond between the ligand and the receptor, or the ligand complex and the receptor.
  • the response that results from the forming ofthe binding pair can include, for example, intemalization ofthe ligand or the ligand complex bound to the cell surface receptor.
  • the binding pair between a receptor and a ligand or ligand complex can also be aided by the association of another receptor or another polypeptide molecule for facilitation ofthe subsequent cellular response, such as for example, intemalization ofthe ligand complex/receptor binding pair.
  • a ligand/receptor binding pair is a pair formed between PDGF (platelet derived growth factor) and the PDGF receptor, a cell surface receptor.
  • Another example of a binding pair is the ligand complex u-PA:PAI-l that binds LRP on a cell surface.
  • An example of a different binding pair is an antigen antibody pair in which the antibody is generated by immunization of a host with the antigen. Specific binding indicates a binding interaction having a low dissociation constant, which distinguishes specific binding from non-specific, background, binding.
  • viral surface protein refers to the protein or polypeptide that makes up the viral surface of a vims.
  • Viral surface proteins useful for the invention include those surface proteins from enveloped vi ses, including retroviruses, and non- enveloped viruses, including, for example, adenovirus.
  • the viral surface proteins may be selected from any viral surface protein, including capsid proteins, from, for example an adeno-virus, an adeno-associated vims, a he ⁇ es simplex vims, a cytomegalovirus, a retrovirus, an influenza vims, a Sindbis vims, and a vesicular stomatitis vims, a retrovims, he ⁇ es simplex vims, cytomegalovirus, and human immune deficiency vims.
  • capsid proteins from, for example an adeno-virus, an adeno-associated vims, a he ⁇ es simplex vims, a cytomegalovirus, a retrovirus, an influenza vims, a Sindbis vims, and a vesicular stomatitis vims, a retrovims, he ⁇ es simplex vims, cytomegalovirus, and human immune
  • intemalization of the vims or "intemalization ofthe particle” as used herein refers to intemalization of a vims or a particle or a vesicle into host cell by contact of a receptor on the cell surface with the ligand portion ofthe viral surface protein or by contact ofthe receptor on the cell surface with the ligand that is affixed to the particle.
  • the vims or particle is then internalized after a binding pair is formed between the receptor and the ligand portion of either the viral surface protein or the altered particle, as the case may be.
  • a "particle” as used herein refers to any vesicle that can encapsulate a polynucleotide coding sequence, including also regulatory sequences, for expression ofthe coding sequence in a host cell.
  • Particles can be, for example, viral particles or non-viral particles.
  • Viral particles can be any enveloped or non-enveloped viral particle and can include a viral genome and heterologous polynucleotide sequences.
  • Exemplary viral particles can be derived from adeno-vims, an adeno-associated vims, he ⁇ es simplex vims, cytomegalovims, a retrovirus, an influenza vims, a Sindbis vims, semliki forest vims and a vesicular stomatitis vims.
  • Exemplary nonviral particles include liposomes such as, for example, those disclosed in U.S. Patent No. 5,422,120, WO 95/13796, WO 94/23697, WO 91/14445 and EP 524.968 Bl, particularly including heterovesicular liposomal particles.
  • an "altered particle" as used herein refers to any vesicle or particle that has been altered with the addition of a ligand portion such that the ligand portion can form a binding pair with a receptor ofthe LDL-receptor family.
  • the ligand portion may also be connected to a viral surface protein portion.
  • the ligand can be any ligand that binds a member ofthe LDL-receptor family.
  • the ligand may be the entire ligand or a biologically active portion thereof, such that the ligand portion retains the ability to form a binding pair with the receptor.
  • the portion of the ligand is affixed to the particle or vesicle by means of affixing peptides or polypeptides to non-protein molecules standard in the art, including but not limited to chemical or UV light crosslinking.
  • the polynucleotide coding region may be inco ⁇ orated into the particle or vesicle before or after the ligand portion is affixed to the particle or vesicle.
  • the altered particle containing a coding sequence and regulatory sequences for expression in a host cell is internalized into a host cell when the ligand affixed to the particle forms a binding pair with the receptor present on the host cell surface.
  • Exemplary expression systems are described below for the construction of recombinant coding sequences in vectors for inco ⁇ oration into a viral genome or for inco ⁇ oration into a particle or vesicle and for intemalization into a host cell in an animal for expression in the animal.
  • the expression systems are useful for the constmction ofthe chimeric polynucleotide encoding a chimeric viral surface protein comprising portions of a ligand and a viral surface protein, and the expression of the chimeric viral surface protein.
  • the expression systems below are also useful for the constmction ofthe coding region of a portion of a ligand that is expressed and affixed to a particle or vesicle for intemalization ofthe particle or vesicle by host cell expressing the receptor for the ligand.
  • the ligand portion may be a peptide or a polypeptide, and retains the biological activity of forming a binding pair with the receptor that the ligand from which it was derived binds in the natural environment.
  • Control elements for use in bacteria include promoters, optionally containing operator sequences, and ribosome binding sites.
  • Useful promoters include sequences derived from sugar metabolizing enzymes, such as galactose, lactose (lac) and maltose. Additional examples include promoter sequences derived from biosynthetic enzymes such as tryptophan (trp), the ⁇ -lactamase (bla) promoter system, bacteriophage ⁇ PL, and T7.
  • synthetic promoters can be used, such as the tac promoter.
  • ⁇ - lactamase and lactose promoter systems are described in Chang et al, Nature (1978) 275: 615, and Goeddel et al, Nature (1979) 281: 544; the alkaline phosphatase, tryptophan (trp) promoter system are described in Goeddel et al, Nucleic Acids Res. (1980) 8: 4057 and EP 36,776 and hybrid promoters such as the tac promoter is described in U.S. Patent No. 4,551 ,433 and deBoer et al, Proc. Natl. Acad. Sci. USA (1983) : 21-25.
  • promoters useful for expression of eukaryotic proteins are also suitable.
  • a person skilled in the art would be able to operably ligate such promoters to the coding sequences of interest, for example, as described in Siebenlist (1980) : 269, using linkers or adaptors to supply any required restriction sites.
  • Promoters for use in bacterial systems also generally will contain a Shine-Dalgamo (SD) sequence operably linked to the DNA encoding the target polypeptide.
  • SD Shine-Dalgamo
  • the signal sequence can be substituted by a prokaryotic signal sequence selected, for example, from the group of the alkaline phosphatase, penicillinase, Ipp, or heat stable enterotoxin II leaders.
  • the origin of replication from the plasmid pBR322 is suitable for most Gram-negative bacteria.
  • numerous other systems for use in bacterial hosts including Gram-negative or Gram-positive organisms such as , 5 , S species such as S or 5 among others
  • Methods for introducing exogenous DNA into these hosts typically include the use of CaCl 2 or other agents, such as divalent cations and DMSO.
  • DNA can also be introduced into bacterial cells by electroporation, nuclear injection, or protoplast fusion as described generally in Sambrook (1989), cited above These examples are illustrative rather than limiting.
  • the host cell should secrete minimal amounts of proteolytic enzymes.
  • methods of cloning e.g., PCR or other nucleic acid polymerase reactions, are suitable.
  • Prokaryotic cells used to produce the target polypeptide of this invention are cultured in suitable media, as described generally in Sambrook cited above.
  • Expression and transformation vectors have been developed for transformation into many yeasts.
  • expression vectors have been developed for, among others, the following yeasts: 5 , as described in Hinnen A S
  • Control sequences for yeast vectors are known and include promoters regions from genes such as alcohol dehydrogenase (ADH), as described in EP 284,044, enolase, glucokinase, glucose-6-phosphate isomerase, glyceraldehyde-3-phosphate-dehydrogenase (GAP or GAPDH), hexokinase, phosphofructokinase, 3 -phosphogly cerate mutase, and pymvate kinase (PyK), as described in EP 329,203.
  • the yeast P O gene encoding acid phosphatase, also provides useful promoter sequences, as described in Myanohara et al, Proc. Natl.
  • promoter sequences for use with yeast hosts include the promoters for 3-phosphoglycerate kinase, as described in Hitzeman et al, J. Biol. Chem. (1980) : 2073, or other glycolytic enzymes, such as pymvate decarboxylase, triosephosphate isomerase, and phosphoglucose isomerase, as described in Hess et al, J. Ad . En yme Re . (1968) 1 149 and Holland et al, Biochemistry (1978) :4900.
  • Inducible yeast promoters having the additional advantage of transcription controlled by growth conditions, include from the list above and others the promoter regions for alcohol dehydrogenase 2, isocytochrome C, acid phosphatase, degradative enzymes associated with nitrogen metabolism, metallothionein, glyceraIdehyde-3-phosphate dehydrogenase, and enzymes responsible for maltose and galactose utilization.
  • suitable vectors and promoters for use in yeast expression are further described in Hitzeman, EP 073,657.
  • Yeast enhancers also are advantageously used with yeast promoters.
  • synthetic promoters which do not occur in nature also function as yeast promoters.
  • upstream activating sequences (UAS) of one yeast promoter may be joined with the transcription activation region of another yeast promoter, creating a synthetic hybrid promoter.
  • hybrid promoters include the ADH regulatory sequence linked to the GAP transcription activation region, as described in U.S. Patent Nos. 4,876,197 and 4,880,734.
  • Other examples of hybrid promoters include promoters which consist of the regulatory sequences of either the A , GA , GA , or P O genes, combined with the transcriptional activation region of a glycolytic enzyme gene such as GAP or Py , as described in EP 164,556.
  • a yeast promoter can include naturally occurring promoters of non-yeast origin that have the ability to bind yeast RNA polymerase and initiate transcription.
  • yeast expression vectors Other control elements which may be included in the yeast expression vectors are terminators, for example, from GAP and from the enolase gene, as described in Holland et al, J. Biol. Chem. (1981) : 1385, and leader sequences which encode signal sequences for secretion.
  • DNA encoding suitable signal sequences can be derived from genes for secreted yeast proteins, such as the yeast invertase gene as described in EP 012,873 and JP 62,096,086 and the ⁇ -factor gene, as described in U.S. Patent Nos. 4,588,684, 4,546,083 and 4,870,008; EP 324,274; and WO 89/02463.
  • leaders of non-yeast origin such as an interferon leader, also provide for secretion in yeast, as described in EP 060,057.
  • Methods of introducing exogenous DNA into yeast hosts are well known in the art, and typically include either the transformation of spheroplasts or of intact yeast cells treated with alkali cations.
  • Transformations into yeast can be carried out according to the method described in Van Solingen et al, J. Bact. (1977) :946 and Hsiao et al, Proc. Natl. Acad. Sci. USA (1979) :3829.
  • other methods for introducing DNA into cells such as by nuclear injection, electroporation, or protoplast fusion may also be used as described generally in Sambrook et al, cited above.
  • the native target polypeptide signal sequence may be substituted by the yeast invertase, ⁇ -factor, or acid phosphatase leaders.
  • the origin of replication from the 2 ⁇ plasmid origin is suitable for yeast.
  • a suitable selection gene for use in yeast is the trpl gene present in the yeast plasmid described in Kingsman et al, Gene (1979) : 141 or Tschemper et al, Gene (1980) 157.
  • the trpl gene provides a selection marker for a mutant strain of yeast lacking the ability to grow in tryptophan.
  • Leu2-def ⁇ cient yeast strains (ATCC 20,622 or 38,626) are complemented by known plasmids bearing the Leu2 Gene.
  • a sequence encoding a yeast protein can be linked to a coding sequence of the polypeptide to produce a fusion protein that can be cleaved intracellularly by the yeast cells upon expression.
  • a yeast leader sequence is the yeast ubiquitin gene.
  • Baculovims expression vectors are recombinant insect vimses in which the coding sequence for a foreign gene to be expressed is inserted behind a baculovims promoter in place of a viral gene, e.g., polyhedrin, as described in Smith and Summers, U.S. Pat. No., 4,745,051.
  • An expression construct herein includes a DNA vector useful as an intermediate for the infection or transformation of an insect cell system, the vector generally containing DNA coding for a baculovims transcriptional promoter, optionally but preferably, followed downstream by an insect signal DNA sequence capable of directing secretion of a desired protein, and a site for insertion of the foreign gene encoding the foreign protein, the signal DNA sequence and the foreign gene being placed under the transcriptional control of a baculovims promoter, the foreign gene herein being the coding sequence of the polypeptide.
  • the promoter for use herein can be a baculovims transcriptional promoter region derived from any of the over 500 baculoviruses generally infecting insects, such as, for example, the Orders Lepidoptera, Diptera, Orthoptera, Coleoptera and Hymenoptera including, for example, but not limited to the viral DNAs o Auto rapho call ornica MNPV, Bom y mori NPV, rrichoplusia ni MNPV, Rachlplusia ou MNPV or Galleria mellonella MNPV, Aedes ae ypti, rosophila melano aster, Spodoptera ru iperda, and richoplusia ni.
  • the baculovims transcriptional promoter can be, for example, a baculovims immediate-early gene IEI or IEN promoter; an immediate-early gene in combination with a baculovims delayed-early gene promoter region selected - 21 -
  • the immediate-early or delayed-early promoters can be enhanced with transcriptional enhancer elements.
  • Particularly suitable for use herein is the strong polyhedrin promoter of the baculovims, which directs a high level of expression of a DNA insert, as described in Friesen et al. (1986) "The Regulation of Baculovims Gene Expression” in: THE MOLECULAR BIOLOGY OF BACULOVIRUSES (W.Doerfler, ed.); EP 127,839 and EP 155,476; and the promoter from the gene encoding the plO protein, as described in Ylak et al, J. Gen. irol. (1988) :765-776.
  • the plasmid for use herein usually also contains the polyhedrin polyadenylation signal, as described in Miller et al, Ann. Re .
  • DNA encoding suitable signal sequences can also be included and is generally derived from genes for secreted insect or baculovims proteins, such as the baculovims polyhedrin gene, as described in Carbonell et al, Gene (1988) :409, as well as mammalian signal sequences such as those derived from genes encoding human ⁇ -interferon as described in Maeda et al, Nature (1985) -.592-594; human gastr in-releasing peptide, as described in Lebacq-Verheyden et al, Mol Cell.
  • baculoviral strains and variants and corresponding permissive insect host cells from hosts such as Spodoptera ru iperda (cate ⁇ illar), Aedes ae ypti (mosquito), Aedes al opictus (mosquito), rosophila melano aster (fruitfly), and Bom y mori host cells have been identified and can be used herein. See, for example, the description in Luckow et al, Bio/Technologwy (198%) : 47-55, Miller et al, in GENETIC ENGINEERING (Setlow, J.K. et al. eds.), Vol. 8 (Plenum Publishing, 1986), pp.
  • vi ses may be used as the vims for transfection of host cells such as Spodoptera rugiperda cells.
  • baculovims genes in addition to the polyhedrin promoter may be employed to advantage in a baculovims expression system. These include immediate-early (alpha), delayed-early (beta), late (gamma), or very late (delta), according to the phase of the viral infection during which they are expressed. The expression of these genes occurs sequentially, probably as the result of a "cascade" mechanism of transcriptional regulation.
  • the immediate-early genes are expressed immediately after infection, in the absence of other viral functions, and one or more of the resulting gene products induces transcription of the delayed-early genes.
  • Some delayed-early gene products induce transcription of late genes, and finally, the very late genes are expressed under the control of previously expressed gene products from one or more of the earlier classes.
  • LEI a preferred immediate-early gene of Autographo call ornica nuclear polyhedrosis vims (AcMNPV).
  • IEI is pressed in the absence of other viral functions and encodes a product that stimulates the transcnption of several genes of the delayed-early class, including the preferred 39K gene, as described in Guarino and Summers, J. irol. (1986) 7:563-571 and J. irol (1987) : 2091-2099 as well as late genes, as described in Guanno and Summers, irol (1988) :444-451.
  • Immediate-early genes as described above can be used in combination with a baculovims gene promoter region of the delayed-early category. Unlike the immediate-early genes, such delayed-early genes require the presence of other viral genes or gene products such as those of the immediate-early genes.
  • the combination of immediate-early genes can be made with any of several delayed-early gene promoter regions such as 39K or one of the delayed-early gene promoters found on the wdlll fragment of d e baculovims genome. In the present instance, the 39 K promoter region can be linked to the foreign gene to be expressed such that expression can be further controlled by the presence of IEI, as described in L. A.
  • enhancement of the expression of heterologous genes can be realized by the prescence of an enhancer sequence in direct cis linkage with the delayed-early gene promoter region.
  • enhancer sequences are characterized by their enhancement of delayed-early gene expression in situations where the immediate-early gene or its product is limited.
  • the hr5 enhancer sequence can be linked directly, in cis, to the delayed-early gene promoter region, 39K, thereby enhancing the expression of the cloned heterologous DNA as described in Guarino and Summers (1986a), (1986b), and Guarino et al. (1986).
  • the polyhedrin gene is classified as a very late gene. Therefore, transcription from the polyhedrin promoter requires the previous expression of an unknown, but probably large number of other viral and cellular gene products. Because of this delayed expression of the polyhedrin promoter, state-of-the-art BEVs, such as the exemplary BEV system described by Smith and Summers in, for example, U.S. Pat. No., 4,745,051 will express foreign genes only as a result of gene expression from the rest of the viral genome, and only after the viral infection is well underway. This represents a limitation to the use of existing BEVs. The ability of the host cell to process newly synthesized proteins decreases as the baculovims infection progresses.
  • gene expression from the polyhedrin promoter occurs at a time when the host cell's ability to process newly synthesized proteins is potentially diminished for certain proteins such as human tissue plasminogen activator.
  • the expression of secretory glycoproteins in BEV systems is complicated due to incomplete secretion of the cloned gene product, thereby trapping the cloned gene product within the cell in an incompletely processed form.
  • an insect signal sequence can be used to express a foreign protein that can be cleaved to produce a mature protein
  • the present invention is preferably practiced with a mammalian signal sequence appropriate for the gene expressed.
  • An exemplary insect signal sequence suitable herein is the sequence encoding for a Lepidopteran adipokinetic hormone (AKH) peptide.
  • the AKH family consists of short blocked neuropeptides that regulate energy substrate mobilization and metabolism in insects.
  • a DNA sequence coding for a Lepidopteran Manduca se ta AKH signal peptide can be used.
  • Other insect AKH signal peptides, such as those from the Orthoptera Schistocerca gregaria locus can also be employed to advantage.
  • Another exemplary insect signal sequence is the sequence coding for Drosophila cuticle proteins such as CPI, CP2, CP3 or CP4.
  • the desired DNA sequence can be inserted into the transfer vector, using known techniques.
  • An insect cell host can be cotransformed with the transfer vector containing the inserted desired DNA together with the genomic DNA of wild type baculovims, usually by cotransfection.
  • the vector and viral genome are allowed to recombine resulting in a recombinant vims that can be easily identified and purified.
  • the packaged recombinant vims can be used to infect insect host cells to express a desired polypeptide.
  • Typical promoters for mammalian cell expression of the polypeptides of the invention include the SV40 early promoter, the CMV promoter, the mouse mammary tumor vims LTR promoter, the adenovims major late promoter (Ad MLP), and the he ⁇ es simplex vims promoter, among others.
  • Other non-viral promoters such as a promoter derived from the murine metallothionein gene, will also find use in mammalian constmcts.
  • Mammalian expression may be either constitutive or regulated (inducible), depending on the promoter. Typically, transcription termination and polyadenylation sequences will also be present, located 3' to the translation stop codon.
  • a sequence for optimization of initiation of translation located 5' to the polypeptide coding sequence, is also present.
  • transcription terminator/polyadenylation signals include those derived from SV40, as described in Sambrook et al. (1989), cited previously.
  • Introns, containing splice donor and acceptor sites, may also be designed into the constmcts of the present invention.
  • Enhancer elements can also be used herein to increase expression levels of the mammalian constmcts. Examples include the SV40 early gene enhancer, as described in Dijkema et al, , EMBO J. (1985) :761 and the enhancer/promoter derived from the long terminal repeat (LTR) of the Rous Sarcoma Vims, as described in Gorman et al, Proc. Natl. Acad. Sci. USA (1982b) 79:6777 and human cytomegalovims, as described in Boshart et al, Cell (1985) :521.
  • LTR long terminal repeat
  • a leader sequence can also be present which includes a sequence encoding a signal peptide, to provide for the secretion of the foreign protein in mammalian cells.
  • a leader sequence can also be present which includes a sequence encoding a signal peptide, to provide for the secretion of the foreign protein in mammalian cells.
  • processing sites encoded between the leader fragment and the gene of interest such that the leader sequence can be cleaved either in i o or in itro.
  • the adenovirus tripartite leader is an example of a leader sequence that provides for secretion of a foreign protein in mammalian cells.
  • the mammalian expression vectors can be used to transform any of several mammalian cells.
  • Methods for introduction of heterologous polynucleotides into mammalian cells include dextran-mediated transfection, calcium phosphate precipitation, polybrene mediated transfection, protoplast fusion, electroporation, encapsulation of the polynucleotide(s) in liposomes, and direct microinjection of the DNA into nuclei.
  • dextran-mediated transfection calcium phosphate precipitation
  • polybrene mediated transfection protoplast fusion
  • electroporation electroporation
  • encapsulation of the polynucleotide(s) in liposomes and direct microinjection of the DNA into nuclei.
  • General aspects of mammalian cell host system transformations have been described by Axel in U.S. Patent No. 4,399,216.
  • cells can be targeted with vi ses or particles containing molecular contents for delivery in a cell or tissue specific manner.
  • the molecular contents include genes for expression in target cells and also include therapeutics or other molecules.
  • chimeric viral surface polypeptides including a portion of a ligand for binding to a cell surface receptor of the LDL-receptor family and a portion of a viral surface protein for inco ⁇ oration of a vims or particle.
  • a vims or particle is inco ⁇ orated by the chimeric viral surface polypeptides and used to target cells expressing receptors that bind the ligand portion of the chimera.
  • the vims that is inco ⁇ orated may be any vims, including but not limited to an adeno-vims, an adeno-associated vims, a retrovirus, a Sindbis vims, and a BK vims.
  • the viral genomes of these vimses are particularly well - 27 -
  • the particles that are inco ⁇ orated and internalized can be any particle capable of containing and delivering molecular contents to a target cell.
  • particles useful for the invention include, but are not limited to, for example, liposomes, including heterovesicular liposomes and cyclodextrin liposomes.
  • the liposomes are also useful in the invention for constmction of altered particles described below.
  • the chimeric viral surface polypeptide of the invention is composed of two portions: a viral surface protein portion and a ligand portion.
  • the viral surface protein portion of the invention can be derived from any vims, enveloped or non-enveloped.
  • the viral surface protein portion of the chimera can be derived from, for example, surface proteins of an adeno-vims, an adeno-associated vims, a he ⁇ es simplex vims, a cytomegalovirus, a retrovirus, an influenza vims, a Sindbis vims, a semliki forest vims or a vesicular stomatitis vims.
  • the viral surface protein portion can be the entire viral surface protein, or a portion of it.
  • the portion ofthe viral surface protein includes that portion that allows the surface protein to inco ⁇ orate into a vims or particle.
  • the ligand portion ofthe chimera is derived from a ligand specific for a receptor of the LDL-receptor family.
  • the ligand portion can be composed of all ofthe ligand or only a portion of it.
  • the essential part ofthe ligand is the portion ofthe ligand that binds the receptor or that allows the receptor-ligand interaction to occur.
  • the chimera is constructed so that binding ofthe ligand to the receptor is possible and is retained to some extent from the native molecule.
  • the ligand is selected, for example, from the following known ligands of LDL-receptors, including, but not limited to serine protease inhibitors (SERPINs), including, for example, PAI-1, protease nexin 1, ⁇ -1 -antitrypsin and ⁇ -1- antichymotrypsin.
  • SERPINs serine protease inhibitors
  • PAI-1 protease nexin 1
  • ⁇ -1 -antitrypsin ⁇ -1-antichymotrypsin
  • the ligand can also be, for example, TFPI, and other ligands known to bind a receptor ofthe LDL-receptor family.
  • the ligand of the invention may also be defined in terms of a ligand complex of more than one polypeptide complexed together and capable of binding as a complex to a receptor ofthe LDL-receptor family.
  • complexes include PA1-1 bound to uPA, PAI-1 bound to tPA, and ⁇ -1 -antitrypsin bound to PSA.
  • PAI-1 :uPA complex binds, for example, LRP on a cell surface.
  • the ligand portion comprises the parts ofthe ligand complex that are necessary for binding to the receptor and for intemalization of the complex by the receptor-mediated mechanism of intemalization into the cell.
  • Example 2 The Chimeras are Specific for a Cell Surface Protein or Complex
  • a ligand is expressed on the vims or other gene delivery particle and this binds to and is internalized by a cell expressing the receptor.
  • the specificity of this event is dependent on the amount and distribution ofthe receptor on the various cell types, including the target cell.
  • the receptor already has the ligand bound to it, eg., erythropoetin bound to the EPO receptor, then a gene delivery particle is not able to bind to that cell.
  • the gene delivery particle is decorated with a ligand, which recognizes a ligand:receptor complex.
  • a gene delivery particle expressing PAI-1 will recognize and to bind covalently to active two chain uPA bound to the uPAR receptor. In this way only cells which are actively involved in cell surface plasminogen activation, and are displaying active receptor bound uPA, will be targeted by the gene delivery particle. After formation ofthe particle:uPA:uPAR complex, efficient intemalization ofthe particle will occur via transfer to LRP or related scavenger receptors. The invention thus achieves enhanced specificity for target cells.
  • Constmction ofthe Chimeric Viral Surface Polypeptide is achieved by employing techniques known in the art of recombinant DNA technology.
  • the expression ofthe chimera is followed by viral budding from the cell, and results in a vims inco ⁇ orated by the chimera and displaying the chimera on the envelope of an external portion ofthe vims.
  • the chimera is constmcted independently and used to form a composition that can inco ⁇ orate into a vims or particle
  • the chimera can be constructed and expressed by any expression system known in the art, including, for example, those disclosed herein. Once the chimera is expressed, it is used to form a composition that is mixed with a viral particle, or other particle for inco ⁇ oration of the vims or particle by the chimera.
  • Example 4 The Inco ⁇ orated Particle is Exposed to Target Cells
  • the vims or particle that has been inco ⁇ orated by the chimeric viral surface polypeptide is then administered to the animal for exposure to target cells.
  • the target cells of the invention express receptors of the LDL-receptor family, including but not limited to LDLR, VLDLR-1, VLDLR-2, LRP, and gp330.
  • LDLR low-denotyl-receptor
  • VLDLR-1 VLDLR-1
  • VLDLR-2 VLDLR-2
  • LRP LRP
  • gp330 receptors of the LDL-receptor family
  • ligands that bind receptors ofthe LDL-receptor family are internalized after binding their receptors.
  • the vims or particle inco ⁇ orated by the chimera is internalized with its ligand portion after binding a receptor.
  • PAI-1 ligand A particular example where the binding pair ofthe ligand and the receptor accomplishes the intemalization ofthe ligand in those cells expressing the receptor is the example ofthe PAI-1 ligand, and PAI-1 ligand complexes.
  • PAI-1 binds uPAR bound uPA on the cell surface and then the newly formed complex of PAI-l:uPA binds LRP, also on the cell surface.
  • PA1-1 forms a covalent bond with uPA which accounts in part for the efficient intemalization of this ligand complex.
  • a vims or particle is internalized when the ligand portion ofthe chimeric viral surface protein comprising, for example, the portion of PA1-1 sufficient for binding uPAR bound uPA and the portion also sufficient for then binding LRP, binds uPA and then binds LRP.
  • the invention is not limited to any theories of mechanism, the intemalization of ligands via the LRP pathway may bring the additional advantage that processing ofthe viral or particle contents occurs under lysosomal conditions including acidic pH which may facilitate efficient release ofthe viral or particle contents into the cell.
  • Example 5 Altered Particles The invention also includes an altered particle for cell-specific delivery.
  • the altered particle is constmcted by attaching a portion of a ligand specific for a receptor of the LDL-receptor family to a particle and using the ligand to target cells for intemalization of the particle and its molecular contents.
  • Altered particles contain molecular contents that have a ligand portion attached to the particle.
  • the ligand portion is derived from the ligands of receptors of the LDL-receptor family, including those described herein.
  • the ligand portion retains at least the portion specific for binding the receptor, and sufficient portion for attaching to the particle.
  • the ligand portion forms a ligand complex
  • the ligand portion retains in addition a portion capable of binding to the polypeptide or polypeptides of that form the ligand complex.
  • the intemalization ofthe ligand-attached altered particle occurs by binding ofthe ligand portion to the receptor on the cell surface.
  • covalent binding occurs between the ligand portion comprising PAI-1 and uPAR bound uPA.
  • the ligand complex also still attached to the particle, then binds the cell surface receptor LRP and is internalized in the cell
  • the ligand or ligand portion is attached to the particle by any means known in the art for such manipulation, including chemical crosslinking, photopolymerization, UV cross-linking, and other techniques known in the art.
  • the molecular contents ofthe vimses and particles include, but are not limited to, coding sequences, and their regulatory sequences and vectors, for expression of polypeptides in the target cells.
  • the molecular contents ofthe particles also includes polynucleotides such as antisense oligonucleotides and ribozymes for delivery to the cell.
  • the contents also include any number of therapeutics, including polypeptides or proteins, drugs, small molecules including peptides and peptoids, and combinations of all of these. Where an altered particle is concerned, the altered particle can be filled with molecular contents before or after the alteration ofthe particle by attaching a ligand portion.
  • polypeptides expressable in a target cell by the invention can be any polypeptide, including, for example, the coding sequence from any protein or polypeptide or part of a protein or polypeptide having biological activity including, but not limited to, for example, a cytokine, a protein hormone, an enzyme, a protease, a protease inhibitor, a growth factor, a differentiation factor, cell surface receptor, or an antibody or antigen.
  • any of a number of viral vectors can be used, as described in Jolly, Cancer Gene Therapy : 51-64 (1994).
  • the coding sequence can be inserted into plasmids designed for expression in retroviral vectors, as described in Kimura et al, uman Gene Therapy (1994) : 845- 852, adenoviral vectors, as described in Connelly et al, uman Gene Therapy (1995) : 185-193, adeno-associated viral vectors, as described in Kaplitt et al, Nature Genetics (1994) : 148-153 and Sindbis vectors.
  • Promoters that are suitable for use with these vectors include, for example, the Moloney retroviral LTR, CMV promoter and the mouse albumin promoter. Replication incompetent free vims can be produced and injected directly into the animal or human or by transduction of an autologous cell e i o, followed by injection in i o as described in Zatloukal et al, Proc. Natl. Acad. Sci. USA (1994) : 5148-5152.
  • Expression of the coding sequence in i o upon delivery for gene therapy pu ⁇ oses by viral vectors can be regulated for maximal efficacy and safety by use of regulated gene expression promoters as described in Gossen et al, Proc. Natl. Acad. Sci. USA (1992) :5547-5551.
  • the coding sequence can be regulated by tetracycline responsive promoters. These promoters can be regulated in a positive or negative fashion by treatment with the regulator molecule.
  • molecular contents for delivery to target cells can include in addition, other therapeutic agents, for example, proteins, polypeptides, non-protein therapeutics, ribozymes, antisense oligonucleotides, peptides, peptoids, other small molecules, and dmgs.
  • therapeutic agents for example, proteins, polypeptides, non-protein therapeutics, ribozymes, antisense oligonucleotides, peptides, peptoids, other small molecules, and dmgs.
  • Example 7 Administration of the Particles Inco ⁇ orated hy the Chimeras A particle inco ⁇ orated by a chimera of the invention, or the altered particle, are administered by any means known for the delivery of particles or vimses to an animal or human, including delivery locally, intravenously, by particle gun, pump, catheter, cannulization, inhalation or other means known in the art.
  • the vims or particle may be administered in a pharmaceutically acceptable composition including but not limited to DepofoamTM and FocalgelTM.
  • the vims, particle or altered particle is internalized by cells mat express the receptor of the LDL-receptor family with which the ligand forms a binding pair.
  • a coding sequence is expressed, or the contents are released into the cell.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Des particules virales et non virales peuvent être incorporées par des polypeptides chimères de surface virale qui sont construits de façon à inclure une partie d'un polypeptide de surface virale et une partie d'un ligand spécifique d'un récepteur de la famille des récepteurs de lipoprotéines de basse densité (LDL). Les particules incorporées par les chimères peuvent cibler des cellules spécifiques du type de récepteur auquel la chimère est associée, et elles peuvent être intégrées à ces cellules. Un type de réalisation de cette invention concerne des chimères construites avec une partie faisant office de ligand d'un inhibiteur de sérine protéase (SERPIN), par exemple PAI-1, servant à cibler des cellules exprimant un récepteur d'uPA (uPAR) lié à un activateur du plasminogène d'urokinase (uPA), et permettant de constituer un complexe intériorisable par contact avec un récepteur de surface de cellule LRP. Conformément à l'invention, lorsque la particule est intériorisée dans la cellule cible, tout génome ou polynucléotide codant un polypeptide en vue de son expression qui est contenu dans la particule virale ou non virale se trouve également intériorisé. L'invention se rapporte par conséquent à des procédures de thérapie génique spécifique de certaines cellules.
PCT/US1996/019196 1995-12-28 1996-12-02 Polypeptides chimeres de surface virale, specifiques d'un recepteur, pour l'incorporation et l'interiorisation d'une particule et d'un virus dans des cellules cibles WO1997024453A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CA002240578A CA2240578A1 (fr) 1995-12-28 1996-12-02 Polypeptides chimeres de surface virale, specifiques d'un recepteur, pour l'incorporation et l'interiorisation d'une particule et d'un virus dans des cellules cibles
JP52432697A JP2001519647A (ja) 1995-12-28 1996-12-02 標的細胞中へのウイルスおよび粒子の取り込みおよびインターナリゼーションのためのレセプター特異的キメラウイルス表面ポリペプチド
EP96946385A EP0880596A1 (fr) 1995-12-28 1996-12-02 Polypeptides de la surface virale, chimeres et recepteur-specifiques, pour l'incorporation et l'internalisation de virus ou de particules dans des cellules cibles

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58013995A 1995-12-28 1995-12-28
US08/580,139 1995-12-28

Publications (1)

Publication Number Publication Date
WO1997024453A1 true WO1997024453A1 (fr) 1997-07-10

Family

ID=24319876

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1996/019196 WO1997024453A1 (fr) 1995-12-28 1996-12-02 Polypeptides chimeres de surface virale, specifiques d'un recepteur, pour l'incorporation et l'interiorisation d'une particule et d'un virus dans des cellules cibles

Country Status (3)

Country Link
EP (1) EP0880596A1 (fr)
JP (1) JP2001519647A (fr)
WO (1) WO1997024453A1 (fr)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6057155A (en) * 1995-11-28 2000-05-02 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
EP1006797A1 (fr) * 1996-06-03 2000-06-14 Case Western Reserve University Transfert genique a mediation par recepteur de complexe enzymatique a base de serpine
WO2000046376A2 (fr) * 1999-02-05 2000-08-10 Eberhard Hildt Particules s'utilisant en therapie genique
WO2000053722A2 (fr) * 1999-03-10 2000-09-14 Phogen Limited Administration de substances a des cellules
US6127525A (en) * 1995-02-21 2000-10-03 Cornell Research Foundation, Inc. Chimeric adenoviral coat protein and methods of using same
WO2001008708A2 (fr) * 1999-07-29 2001-02-08 Case Western Reserve University Administration amelioree par l'intermediaire d'un recepteur du complexe enzyme inhibiteur de la serine protease
US6455314B1 (en) 1998-09-11 2002-09-24 Genvec, Inc. Alternatively targeted adenovirus
US6576456B2 (en) 1995-02-21 2003-06-10 Cornell Research Foundation, Inc. Chimeric adenovirus fiber protein
US6929946B1 (en) 1998-11-20 2005-08-16 Crucell Holland B.V. Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells
US6951755B2 (en) 1994-09-08 2005-10-04 Genvec, Inc. Vectors and methods for gene transfer
US7026282B1 (en) 1998-07-01 2006-04-11 Cancerforskningsfonden AF 1989 (Fonden Til Fremme AF Exsperimentel Cancerforskning) Peptide antagonists of the human urokinase receptor and method for selecting them
WO2012035034A1 (fr) 2010-09-14 2012-03-22 F. Hoffmann-La Roche Ag Polypeptide de fusion à serpine-doigt de zinc

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993020221A1 (fr) * 1992-04-03 1993-10-14 Young Alexander T Therapie genique utilisant des vecteurs viraux cibles
WO1993024141A1 (fr) * 1992-05-28 1993-12-09 The University Of Toledo Apport d'un compose cytotoxique dans une cellule cancereuse au moyen d'un canal de materiau activateur du plasminogene
WO1993025234A1 (fr) * 1992-06-08 1993-12-23 The Regents Of The University Of California Procedes et compositions permettant de cibler des tissus specifiques
WO1994027643A1 (fr) * 1993-06-01 1994-12-08 Targeted Genetics Corporation Vecteurs de fusion d'enveloppe utilises dans l'apport de genes

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993020221A1 (fr) * 1992-04-03 1993-10-14 Young Alexander T Therapie genique utilisant des vecteurs viraux cibles
WO1993024141A1 (fr) * 1992-05-28 1993-12-09 The University Of Toledo Apport d'un compose cytotoxique dans une cellule cancereuse au moyen d'un canal de materiau activateur du plasminogene
WO1993025234A1 (fr) * 1992-06-08 1993-12-23 The Regents Of The University Of California Procedes et compositions permettant de cibler des tissus specifiques
WO1994027643A1 (fr) * 1993-06-01 1994-12-08 Targeted Genetics Corporation Vecteurs de fusion d'enveloppe utilises dans l'apport de genes

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CUBELLIS, M.V., ET AL .: "RECEPTOR-MEDIATED INTERNALIZATION AND DEGRADATION OF UROKINASE IS CAUSED BY ITS SPECIFIC INHIBITOR PAI-1", THE EMBO JOURNAL, vol. 9, no. 4, 1990, pages 1079 - 1085, XP002027849 *
WILLNOW, T.E., ET AL .: "MOLECULAR DISSECTION OF LIGAND BINDING SITES ON THE LOW DENSITY LIPOPROTEIN RECEPTOR-RELATED PROTEIN", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 269, no. 22, June 1994 (1994-06-01), pages 15827 - 15832, XP002027850 *

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6951755B2 (en) 1994-09-08 2005-10-04 Genvec, Inc. Vectors and methods for gene transfer
US6576456B2 (en) 1995-02-21 2003-06-10 Cornell Research Foundation, Inc. Chimeric adenovirus fiber protein
US6153435A (en) * 1995-02-21 2000-11-28 Cornell Research Foundation, Inc. Nucleic acid that encodes a chimeric adenoviral coat protein
US6127525A (en) * 1995-02-21 2000-10-03 Cornell Research Foundation, Inc. Chimeric adenoviral coat protein and methods of using same
US6057155A (en) * 1995-11-28 2000-05-02 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
EP1006797A1 (fr) * 1996-06-03 2000-06-14 Case Western Reserve University Transfert genique a mediation par recepteur de complexe enzymatique a base de serpine
EP1006797A4 (fr) * 1996-06-03 2001-09-12 Univ Case Western Reserve Transfert genique a mediation par recepteur de complexe enzymatique a base de serpine
US7026282B1 (en) 1998-07-01 2006-04-11 Cancerforskningsfonden AF 1989 (Fonden Til Fremme AF Exsperimentel Cancerforskning) Peptide antagonists of the human urokinase receptor and method for selecting them
US6455314B1 (en) 1998-09-11 2002-09-24 Genvec, Inc. Alternatively targeted adenovirus
US6929946B1 (en) 1998-11-20 2005-08-16 Crucell Holland B.V. Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells
US7018826B1 (en) * 1999-02-05 2006-03-28 Island Pharmaceuticals Ltd. Particles for gene therapy
WO2000046376A3 (fr) * 1999-02-05 2000-11-16 Eberhard Hildt Particules s'utilisant en therapie genique
WO2000046376A2 (fr) * 1999-02-05 2000-08-10 Eberhard Hildt Particules s'utilisant en therapie genique
WO2000053722A3 (fr) * 1999-03-10 2001-07-12 Phogen Ltd Administration de substances a des cellules
WO2000053722A2 (fr) * 1999-03-10 2000-09-14 Phogen Limited Administration de substances a des cellules
WO2001008708A3 (fr) * 1999-07-29 2002-01-24 Univ Case Western Reserve Administration amelioree par l'intermediaire d'un recepteur du complexe enzyme inhibiteur de la serine protease
WO2001008708A2 (fr) * 1999-07-29 2001-02-08 Case Western Reserve University Administration amelioree par l'intermediaire d'un recepteur du complexe enzyme inhibiteur de la serine protease
US9403896B2 (en) 2010-09-14 2016-08-02 Hoffmann-La Roche Inc. Serpin-finger fusion polypeptide
WO2012035034A1 (fr) 2010-09-14 2012-03-22 F. Hoffmann-La Roche Ag Polypeptide de fusion à serpine-doigt de zinc

Also Published As

Publication number Publication date
EP0880596A1 (fr) 1998-12-02
JP2001519647A (ja) 2001-10-23

Similar Documents

Publication Publication Date Title
US6903078B1 (en) Combination PDGF, KGF, IGF, and IGFBP for wound healing
WO1997024453A1 (fr) Polypeptides chimeres de surface virale, specifiques d'un recepteur, pour l'incorporation et l'interiorisation d'une particule et d'un virus dans des cellules cibles
US7556941B2 (en) Materials and methods for preparing dimeric growth factors
EP1446478B1 (fr) Facteur de croissance dimerise et materiaux et procedes utilises pour sa production
US20100015117A1 (en) Compositions and methods for targeting a polypeptide to the central nervous system
AU8899298A (en) Lipocalin homologs
KR970705638A (ko) 내피 세포 특이적이고 세포 사이클-의존성인 활성 화합물을 사용한 종양의 유전적 치료법(Genetic therapy of tumours with an endothelium cell-specific active substance which is dependent on the cell cycle)
JP2008109934A (ja) ウロキナーゼレセプターのペプチドリガンド
CN113164623A (zh) 基于arc的衣壳及其用途
US6303369B1 (en) Protein expression system
ES2201718T3 (es) Generacion de productos genicos multiples a partir de proteinas quimericas de fusion, mediante corte con endoproteasas.
WO1997035969A9 (fr) Ligands peptidiques du recepteur de l'urokinase
WO1997012045A1 (fr) Procede d'obtention d'un hote deficient en proteases
Kawase et al. Construction and characterization of a fusion protein with epidermal growth factor and the cell-binding domain of fibronectin
CA2237543A1 (fr) Nouvelle forme d'amphireguline, ses procedes de production et son utilisation ainsi que compositions la contenant
CA2529058A1 (fr) Infiltration accrue de lymphocytes t dans une tumeur provoquee par le mutant light
WO2001066748A2 (fr) Polynucleotides exprimes entiers et polypeptides codes par ces derniers
CA2240578A1 (fr) Polypeptides chimeres de surface virale, specifiques d'un recepteur, pour l'incorporation et l'interiorisation d'une particule et d'un virus dans des cellules cibles
WO1997003191A1 (fr) Nouveaux analogues de polypeptides du facteur viii:c comprenant des domaines ou des sous-domaines du facteur v
US20040265797A1 (en) Peptide ligands of the urokinase receptor
Winslow et al. Feline B7. 1 and B7. 2 proteins produced from swinepox virus vectors are natively processed and biologically active: potential for use as nonchemical adjuvants
CA2343568A1 (fr) Regulation de reponses immunes a l'aide d'attractine
CN106167524B (zh) 来源于东方蜜蜂的赛卡品肽
KR20130045385A (ko) 세르핀-핑거 융합 폴리펩티드
CA2204020A1 (fr) Systeme de transfert de l'acide nucleique

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): CA JP AM AZ BY KG KZ MD RU TJ TM

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: PAT.BUL.30/97, UNDER INID(81)"DESIGNATED STATES",ADD"EUROPEAN PATENT(AT,BE,CH,DE,DK,ES,FI,FR,GB,GR,IE,IT,LU,MC,NL,PT,SE)";DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

ENP Entry into the national phase

Ref country code: JP

Ref document number: 1997 524326

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref document number: 2240578

Country of ref document: CA

Ref country code: CA

Ref document number: 2240578

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1996946385

Country of ref document: EP

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWP Wipo information: published in national office

Ref document number: 1996946385

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1996946385

Country of ref document: EP